DcR1 (Extracellular Domain) Peptide
- Known as:
- DcR1 (Extracellular Domain) Peptide
- Catalog number:
- 2179P
- Product Quantity:
- 0.05 mg
- Category:
- -
- Supplier:
- Prosci
- Gene target:
- DcR1 (Extracellular Domain) Peptide
Related genes to: DcR1 (Extracellular Domain) Peptide
- Gene:
- TNFRSF10C NIH gene
- Name:
- TNF receptor superfamily member 10c
- Previous symbol:
- -
- Synonyms:
- DcR1, TRAILR3, LIT, TRID, CD263
- Chromosome:
- 8p21.3
- Locus Type:
- gene with protein product
- Date approved:
- 1998-12-04
- Date modifiied:
- 2016-10-05
Related products to: DcR1 (Extracellular Domain) Peptide
Related articles to: DcR1 (Extracellular Domain) Peptide
- Age-related macular degeneration (AMD) and cardiovascular disease (CVD) share numerous risk factors; however, protein biomarkers for AMD are lacking. We investigated whether circulating cardiovascular peptide biomarkers are associated with AMD in the population-based Białystok PLUS cohort. This cross-sectional analysis included 699 participants aged ≥ 50 years (AMD + = 93; AMD⁻ = 606) examined between 2018 and 2023. AMD was graded from fundus photos with the use of the Wisconsin and modified International Classification systems. Ninety-two cardiovascular proteins were quantified in serum with the Olink Target Cardiovascular III panel. Age-adjusted linear or logistic regressions assessed biomarker-AMD associations, and receiver-operating-characteristic (ROC) curves evaluated discriminative performance. After adjustment, AMD+ participants exhibited lower galectin-4 (β = - 0.15, p = 0.043) and TNF-receptor-superfamily-member-10 C (TNFRSF10C) (β = - 0.17, p = 0.037) concentrations and higher von Willebrand factor (vWF) levels (β = 0.22, p = 0.036) versus AMD⁻ individuals. Galectin-4, TNFRSF10C, and vWF predicted AMD with areas under the ROC curve of 0.613 (95% confidence interval [CI] 0.516-0.709), 0.606 (0.520-0.692), and 0.594 (0.500-0.687), respectively. Optimal cut-offs were 4.05 NPX for galectin-4, 5.09 NPX for TNFRSF10C, and 8.03 NPX for vWF, yielding sensitivities/specificities of 57%/63%, 58%/62% and 55%/63%, respectively. Elevated vWF and reduced galectin-4 and TNFRSF10C are independently associated with AMD, suggesting overlapping vascular, inflammatory and apoptotic pathways with CVD. Incorporation of these peptides into risk-stratification algorithms could enhance early AMD detection and motivate mechanistic studies targeting the TRAIL-TNFRSF10C axis and galectin-mediated signaling. - Source: PubMed
Publication date: 2026/06/17
Budnik AgnieszkaTuchliński JakubLisowski ŁukaszMichnowska-Kobylińska MagdalenaDmuchowska Diana AnnaChlabicz MałgorzataSzpakowicz AnnaDubatówka MarlenaKondraciuk MarcinKamiński KarolKonopińska Joanna - This study explores programmed cell death (PCD)-related genes in osteosarcoma through bioinformatics and experimental validation. - Source: PubMed
Publication date: 2026/06/15
Hu BinDu LiLu ChangchunHuang DingdingPan MingmangXue FengShen YuchunDing LiangYin Nuo - Background Glioblastoma (GBM) is characterized by immune dysregulation and epigenetic alterations that contribute to tumor progression. Although tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) signaling has been implicated in tumor biology, the transcriptional and immunological relevance of its decoy receptors, TNF receptor superfamily member 10C and 10D (TNFRSF10C and TNFRSF10D), in gliomas remains incompletely characterized. Methods An integrative multi-omic analysis was performed using The Cancer Genome Atlas (TCGA), Genotype-Tissue Expression (GTEx), and Chinese Glioma Genome Atlas (CGGA) datasets in combination with Gene Expression Profiling Interactive Analysis 3 (GEPIA3), University of Alabama at Birmingham Cancer database (UALCAN), Tumor Immune Estimation Resource 3.0 (TIMER3.0), Search Tool for the Retrieval of Interacting Genes/Proteins (STRING), and MEXPRESS platforms. Gene expression, promoter methylation, molecular subtype distribution, immune infiltration patterns, and clinical associations were evaluated using harmonized analytical workflows and cross-validation across datasets. Results Both receptors demonstrated progressive upregulation from normal brain to lower-grade glioma (LGG) and GBM, with higher expression observed in isocitrate dehydrogenase (IDH)-wildtype tumors. Promoter methylation analysis revealed inverse correlations between CpG methylation and gene expression, suggesting potential epigenetic associations. Immune deconvolution analyses showed consistent associations with myeloid cell populations, including macrophages, neutrophils, and dendritic cells (DCs), alongside limited correlations with T-cell subsets. Protein-protein interaction network analysis indicated that these receptors interact with multiple components of inflammatory and TNF/TRAIL signaling systems. Higher expression showed trends toward shorter progression-free intervals (PFI). Conclusions TNFRSF10C and TNFRSF10D demonstrate reproducible associations with methylation patterns and immune microenvironment characteristics in GBM. These findings highlight potential links between TRAIL decoy receptors and inflammatory tumor states and support further mechanistic investigation. - Source: PubMed
Publication date: 2026/03/25
Khurana Kartik MSaoji AjeetPahuja Heena - In the last decade, methods to investigate the immune status of the tumor microenvironment (TME) and predict immune checkpoint blockade efficacy have been intensively developed as immunoscores or immune signatures. However, since the immunological gene signature is a complex and time-consuming approach, a simpler scoring system using numerical data is needed to evaluate a large number of tumors. We previously established a TME immune-type classification system based on PD-L1 and CD8B gene expression, and 5032 cancer patients were classified into 4 types. Based on the expression levels of immune response-associated genes in each type, these genes were assigned scores ranging 1 to 4, representing a spectrum from immunosuppressive to immunostimulating genes. We herein calculated tumor immune status scoring algorithm (TIMMUSCORA) scores based on the expression data of 300 immune response-associated genes in 5,013 pancancer patients, and investigated the relationship of these scores with the prognosis and other clinicopathological features of cancer patients. Rectal cancers with higher scores than the cut-off value of 0 showed a good prognosis, which was closely associated with the immune response-associated genes PDCD1, GZMB, TNFRSF10C, EBI3, and IRF1. A correlation analysis of the rectal cancer cohort suggested that high TIMMUSCORA scores correlated with high TMB value and the consensus molecular subtyping 1 status, while low scores correlated with WNT gene expression. Therefore, the TIMMUSCORA system has potential in evaluations of the immune status of the TME and the prognosis of solid cancers. - Source: PubMed
Publication date: 2026/04/25
Ikeya TomoatsuKikuchi YasufumiAshizawa TadashiKanematsu AkariMaeda ChieIizuka AkiraYamashita KazueMiyata HaruoNagashima TakeshiUrakami KenichiShimoda YujiOhshima KeiichiMuramatsu KojiSugino TakashiShiomi AkioOhde YasuhisaBando EtsuroSugiura TeiichiMukaigawa TakashiNishimura SeiichiroKenmotsu HirotsuguYamaguchi KenAkiyama Yasuto - This study aimed to screen the specific modules and hub genes of hyperlipidemia. - Source: PubMed
Publication date: 2025/12/10
Zhao ZhiyiCao YinGu AnnaYao Hanxin